KRINGLE PHARMA, INC.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public
- Established
- 2001-12-21
- Employees
- 13
- Market Cap
- -
Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Kringle Pharma, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT05627648
- Locations
- π―π΅
Kawasaki Medical School Hospital, Kurashiki, Okayama, Japan
π―π΅Tohoku University Hospital, Sendai, Miyagi, Japan
π―π΅Nihon University Hospital, Chiyoda-ku, Tokyo, Japan
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Kringle Pharma, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04475224
- Locations
- π―π΅
Spinal Injuries Center, Iizuka, Fukuoka, Japan
π―π΅Hokkaido Spinal Cord Injury Center, Bibai, Hokkaido, Japan
π―π΅Japanese Red Cross Kobe Hospital, Kobe, Hyogo, Japan
Phase I/II Study of KP-100IT in Acute Spinal Cord Injury
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Kringle Pharma, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02193334
- Locations
- π―π΅
Spinal Injuries Center, Iizuka, Fukuoka, Japan
π―π΅Hokkaido Chuo Rosai Hospital Sekison Center, Bibai, Hokkaido, Japan
Β© Copyright 2025. All Rights Reserved by MedPath